• ZARIPOV Sanjarbek Istamovich
  • AKHMEDOV Khalmurad Sadullayevich
  • ABDURAKHMANOVA Nargiza Mirza-Bakhtiyarkhanovna


systemic sclerosis, antinuclear antibodies (ANA), fibrillarin, antifibrillary antibodies (AFA), Raynaud's phenomenon, modified Rodnan skin scale (mRSS)


Systemic sclerosis is a progressive chronic autoimmune rheumatic disease with high morbidity and mortality. Systemic sclerosis a multi-organ disease that affects organs such as the skin, lungs, digestive system, heart, musculoskeletal system, kidneys, causing severe pain and disability, disability and death of patients. The main marker of an abnormal immune response is circulating autoantibodies, which are found in more than 95% of patients with systemic sclerosis. It is important to study the clinical, immunological, diagnostic and prognostic significance of autoantibodies, especially antifibrillary antibodies produced against the fibrillarin protein.


Ахмедов Х. С., Разакова Ф. С., Ахмедова М. С. ЗНАЧЕНИЕ ОПТИМИЗАЦИИ ВТОРИЧНОЙ ПРОФИЛАКТИКИ СИСТЕМНОЙ СКЛЕРОДЕРМИИ В ПОДДЕРЖАНИИ КАЧЕСТВА ЖИЗНИ ЖЕНЩИН РЕПРОДУКТИВНОГО ВОЗРАСТА //Формы и методы социальной работы в различных сферах жизнедеятельности. – 2017. – С. 26-27

Ахмедов Х. С., Карабоева Р. А. Нарушения иммунного гомеостаза у больных системной склеродермией //Иммунология. – 2001. – №. 3. – С. 53.

Ахмедов Х. С. Значение коррекции прогестероновой недостаточности в усилении вторичной профилактики больных системной склеродермией //Врач-аспирант. – 2007. – Т. 17. – №. 2. – С. 92-96.

Соболевский П., Маслинская М., Вечорек М., Лагун З., Малевска А., Рошкевич М., Ницкович Р., Шиманская Э. и Валецка И. (2019). Системный склероз - мультидисциплинарное заболевание: клиника и лечение. Ревматология, 57 (4), 221–233.

Abdurakhmanova N., Akhmedov Kh. Effect of pro-inflammatory cytokine-Interleukin- 6 on the course of ankylosing spondylitis in patients after COVID-19 //Annals of the Rheumatic Diseases. – 2022. – С. 1533-1533.

Abdurakhmanova N. M. et al. Modern methods of treatment of patients with ankylosing spondylitis //International Journal of Advance Scientific Research. – 2022. – Т. 2. – №. 11. – С. 112-118.

Abdurakhmanova N. M. High concentration of tumor necrosis factor in ankylosing spondylitis patients after COVID-19 //British medical journal. – 2022. – Т. 2. – №. 1.2.

Akhmedov K., Abdurakhmanova N., Buranova S. FEATURES OF THE CLINICAL COURSE OF RHEUMATOID SPICE AGAINST THE BACKGROUND OF THE INFLUENCE OF XENOBIOTICS //American Journal of Interdisciplinary Research and Development. – 2023. – Т. 12. – С. 142-147.

Barsotti S, Bellando Randone S, Guiducci S, et al. Systemic sclerosis: a critical digest of the recent literature. Clin Exp Rheumatol 2014; 32: S194-S205.

Bertrand D, Dehay J, Ott J, et al. Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. Transpl Int 2017; 30: 256-265

Castro SV, Jimenez SA. Biomarkers in systemic sclerosis. Biomark Med 2010; 4: 133-147. / Barsotii S, Stagnaro C, Della Rossa A. Systemic sclerosis: a critical digest of the recent literature. Clin Exp Rheumatol 2105; 33 (Suppl 91): S3-14.

Cavazzana, I., Vojinovic, T., Airo’, P. et al. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clinic Rev Allerg Immunol (2022).

Clark, K.E.N., Campochiaro, C., Host, L.V. et al. Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes. Sci Rep 12, 11212 (2022).

Dieudé P, Guedj M, Wipff J, et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum 2009; 60: 3447-3454.

Emmanuel A. Current management of the gastrointestinal complications of systemic sclerosis. Nat Rev Gastroenterol Hepatol 2016; 13: 461-472

Furue M, Mitoma C, Mitoma H, et al. Pathogenesis of systemic sclerosis – current concept and emerging treatments. Immunol Res 2017; 65: 790-797.

Gong, P., Ding, Y., Sun, R. et al. Mesenchymal stem cells alleviate systemic sclerosis by inhibiting the recruitment of pathogenic macrophages. Cell Death Discov. 8, 466 (2022)

Hasegawa M. Biomarkers in systemic sclerosis: their potential to predict clinical courses. J Dermatol 2016; 43: 29-38.

HOFFMANN-VOLD AM, ALLANORE Y, ALVESM et al.: Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 2021; 80: 219-27

Jerjen R, Nikpour M, Krieg T, Denton CP, Saracino AM. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. J Am Acad Dermatol. 2022 Nov;87(5):937-954. doi: 10.1016/j.jaad.2021.10.065. Epub 2022 Feb 4. PMID: 35131402.

Jin J, Chou C, Lima M, et al. Systemic Sclerosis is a Complex Disease Associated Mainly with Immune Regulatory and Inflammatory Genes. Open Rheumatol J 2014; 8: 29-42.

Kayser C, Fritzler MJ. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol. 2015 Apr 15;6:167. doi: 10.3389/fimmu.2015.00167. PMID: 25926833; PMCID: PMC4397862.

Keppeke GD, Satoh M, Kayser C, Matos P, Hasegawa T, Tanaka S, Diogenes L, Amaral RQ, Rodrigues SH and Andrade LEC (2022) A cell-based assay fordetection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation. Front. Immunol. 13:1011110. doi: 10.3389/fimmu. 2022.1011110

Kim S, Park HJ, Lee SI. The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential. Int J Mol Sci. 2022 Dec 18;23(24):16154. doi: 10.3390/ijms232416154. PMID: 36555792; PMCID: PMC9853331.

Kowal-Bielecka O, Kuryliszyn-Moskal A. Twardzina układowa. Reumatologia 2016; Suppl 1: 51-55.

Kucharz EJ, Kopeć-Mędrek M. Systemic sclerosis sine scleroderma. Adv Clin Exp Med 2017; 26: 875-880.

Lee A. Fibrillarin antibodies in systemic sclerosis. Arch Rheumatol. 2021 Oct 18;37(2):311- 312. doi: 10.46497/ArchRheumatol.2022.9038. PMID: 36017207; PMCID: PMC9377177.

Mejia Otero C, Assassi S, Hudson M, Mayes MD, Estrada-Y-Martin R, Pedroza C, Mills TW, Walker J, Baron M, Stevens W, Proudman SM, Nikpour M, Mehra S, Wang M, Fritzler MJ; Canadian Scleroderma Research Group; Australian Scleroderma Cohort Study; Genetics versus Environment in Scleroderma Outcome Study. Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. J Rheumatol. 2017 Jun;44(6):799-805. doi: 10.3899/jrheum.160574. Epub 2017 Apr 1. PMID: 28365584; PMCID: PMC5457664.

Schiopu E, Impens AJ, Phillips K. Digital ischemia in scleroderma spectrum of diseases. Int J Rheumatol 2010; 2010: 923743.

Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437-2444.

TERRIER B, DECHARTRES A, GOUYA H et al.: Cardiac intravoxel incoherent motion diffusion-weighted magnetic resonance imaging with T1 mapping to assess myocardial perfusion and fibrosis in systemic sclerosis: association with cardiac events from a prospective cohort study. Arthritis Rheumatol 2020; 72: 1571-80.

Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification Criteria for Systemic Sclerosis: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747-755.

Walker UA, Clements óJ, Allanore Y, et al. Muscle involvementin systemic sclerosis: points to consider in clinical trials, Rheumatology (Oxford) 2017; 56: v38-v44.

Yang C, Tang S, Zhu D, Ding Y, Qiao J. Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical Features, Gene Susceptibility, and Disease Stratification. Front Med (Lausanne). 2020 Nov 19;7:587773. doi: 10.3389/fmed.2020.587773. PMID: 33330547; PMCID: PMC7710911.

Zhang J, Yang G, Li Q, Xie F. Increased fibrillarin expression is associated with tumor progression and an unfavorable prognosis in hepatocellular carcinoma. Oncol Lett. 2021 Feb;21(2):92. doi: 10.3892/ol.2020.12353. Epub 2020 Dec 6. PMID: 33376525; PMCID: PMC7751345.